Alcohol and risk of liver cancer

Share This Post

Does alcohol increases the risk of liver cancer ? For this question, we got affirmative answers from some experts and professors at the Medical Academic Medical Center of the University of Southern California. Excessive drinking can cause liver cancer, which is a fact that has been established. If diagnosed early, patients have more treatment options, so screening is the key.

So, what are the causes of liver cancer? In most cases, liver cancer is caused by cirrhosis, which is caused by inflammation and scarring of liver cells. There are three main causes of cirrhosis: hepatitis B and hepatitis C viruses; non-alcoholic steatohepatitis (NASH). NASH is caused by fatty liver, and its risk factors include obesity, gastric bypass surgery, high cholesterol and type 2 diabetes. Some NASH patients directly develop liver cancer without cirrhosis. Overweight and alcoholics also face double risks. The third reason is alcoholic liver disease.

Most occasional social drinkers will not contract alcoholic cirrhosis. A reliable way to protect yourself from alcoholic liver disease is to avoid drinking altogether. People who drink a lot of alcohol have a greater risk of liver cancer. Therefore, people who drink too much should be screened for liver cancer. The screening process is simple and non-invasive, and the doctor will perform an ultrasound examination of the liver to detect cysts, obstructions or infections in the liver and to check for cancer. If an abnormality is found on the ultrasound, the doctor will determine if you need additional tests, such as CT scans, MRI, or alpha-fetal protein tests, which can identify the tumor.


For details on best options for liver cancer treatment, do call us at +91 96 1588 1588 or write to

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form